Apixaban to prevent stroke in atrial fibrillation and kidney failure
Part of Brain & nervous system, Heart & circulation, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests apixaban (a blood thinner) to prevent stroke in people with atrial fibrillation or atrial flutter who have very poor kidney function or are on dialysis. If you qualify, you may help researchers find a safer way to lower stroke risk for this higher-risk group.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You can read and sign a consent form (or have a legal representative sign it).
- You are age 18 or older.
- You have atrial fibrillation or atrial flutter that keeps coming back, lasts, or is ongoing.
- Your kidney function is very low (eGFR under 20) for long enough, or you are already on chronic dialysis.
- Your stroke-risk score is high enough that a blood thinner is usually recommended.
- If you can become pregnant, you must test negative and use effective birth control during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two strategies for managing atrial fibrillation (irregular heartbeat) in people on dialysis: one uses a blood thinner called apixaban to prevent strokes, and the other does not. The goal is to find out which approach is safer and more effective for this specific group.
This trial tests whether apixaban, a blood thinner, works well for people with atrial fibrillation who also have heart or circulation conditions. It uses a smartphone app to help track your treatment.
This study tests if apixaban (a newer blood thinner) is safer and works as well as warfarin (a standard blood thinner) for patients on peritoneal dialysis who have atrial fibrillation (an irregular heartbeat). It aims to reduce the risk of stroke and bleeding.
This trial compares two types of blood thinners (vitamin K antagonists and factor Xa inhibitors) versus no blood thinner in people with atrial fibrillation who are on dialysis or have very advanced kidney disease. It aims to see which option is safest and most effective for preventing strokes and bleeds.
This study tests whether a common blood thinner (apixaban) alone is as safe and effective as combining it with another drug (clopidogrel) to prevent future strokes in people who have both atrial fibrillation and narrowing in the arteries leading to the brain. It aims to find the best way to reduce stroke risk while minimizing bleeding.
This trial compares the bleeding risk of two commonly used blood thinners—rivaroxaban and apixaban—in people with atrial fibrillation (AF). If you’re starting an anticoagulant for a new AF diagnosis, this may help doctors choose the safer option for you and others.
Hear when a new Atrial fibrillation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.